Skip to content

Elobixibat

ALIMENTARY TRACT AND METABOLISM

Also known as: A3309, AJG533, AZD7806, elobixibat hydrate, goofice

PMDA approvedATC A06AX09

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Elobixibat is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2018. DrugCentral lists 2 molecular targets, including SLC10A2 and NR1H4. Recorded indications include Chronic constipation.

  • Molecular targets: SLC10A2 and NR1H4 (2 listed in DrugCentral).
  • Indications: Chronic constipation.
  • ATC code: A06AX09 (Other drugs for constipation).
  • Molecular formula: C36H45N3O7S2; molecular weight 695.89 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Chronic constipation

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Ileal sodium/bile acid cotransporterSLC10A2inhibitorIC50 9.28
Bile acid receptorNR1H4unknownIC50 8.92

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2018-01-19PMDA—EA Pharma

ATC classification

ATC codeTherapeutic hierarchy
A06AX09ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Pleurothotonus52.3
Hepatic function abnormal44.0
Interstitial lung disease32.7
Pneumonia aspiration32.4

Chemical structure

Molecular formulaC36H45N3O7S2
Molecular weight695.89 g/mol
CAS number439087-18-0
InChIKeyXFLQIRAKKLNXRQ-UUWRZZSWSA-N
PubChem CID9939892
CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=C(C=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C(SC)=C2)S(=O)(=O)C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Elobixibat used for?

DrugCentral lists the following indications for Elobixibat: Chronic constipation.

How does Elobixibat work?

Its molecular targets in DrugCentral include SLC10A2 (inhibitor) and NR1H4.

When was Elobixibat first approved?

Elobixibat was first approved by the PMDA in 2018.

What is the chemical formula of Elobixibat?

Elobixibat has the molecular formula C36H45N3O7S2 and a molecular weight of 695.89 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2018-01-19
AgencyPMDA
Targets2
Indications1
FormulaC36H45N3O7S2
DrugCentral ID5277
Interactive profile